We are live on ! Find out more
DMAC icon

DiaMedica Therapeutics
DMAC

22 hedge funds and large institutions have $8.24M invested in DiaMedica Therapeutics in 2020 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 7 increasing their positions, 2 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

250% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 2

111% more capital invested

Capital invested by funds: $3.91M → $8.24M (+$4.33M)

47% more funds holding

Funds holding: 15 → 22 (+7)

14% more ownership

Funds ownership: 6.72% → 20.72% (+14%)

Holders
22
Holders Change
+7
Holders Change %
+46.67%
% of All Funds
0.48%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
7
Reduced
2
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SCM
Stonepine Capital Management
Oregon
+$3.41M
2
NCM
Nantahala Capital Management
Connecticut
+$3.1M
3
GPCM
Granite Point Capital Management
Massachusetts
+$1.03M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$665K
5
MHP
Manatuck Hill Partners
Connecticut
+$325K

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$91.3K
2
WVP
Worth Venture Partners
New Jersey
-$67.4K

DMAC Hedge Fund Activity: Q1 2020 in Review

22 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in DiaMedica Therapeutics (DMAC) for Q1 2020, worth a combined $8.24M — up 111% from $3.91M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new DMAC positions and 0 closed out — a net gain of 7 holders — while 7 added to existing stakes and 2 trimmed.

The largest buyer was Stonepine Capital Management, opening a new position worth an estimated $3.41M. The largest seller was Millennium Management, cutting an estimated $91.3K.

  • 22 institutional investors held DiaMedica Therapeutics (DMAC) as of Q1 2020, up from 15 in Q4 2019.
  • Funds reported $8.24M of DiaMedica Therapeutics stock for Q1 2020, up 111% quarter-over-quarter.
  • 7 funds opened new DiaMedica Therapeutics positions in Q1 2020 and 0 closed out, a net change of +7 holders.
  • The largest DiaMedica Therapeutics buyer in Q1 2020 was Stonepine Capital Management, an estimated $3.41M added.
  • The largest DiaMedica Therapeutics seller in Q1 2020 was Millennium Management, an estimated $91.3K sold.

Based on aggregated 13F filings for Q1 2020.